Diagnostic Evaluation and Management of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Initial Diagnostic Evaluation

The American College of Radiology recommends MRI with MRCP as the primary imaging modality for IPMN diagnosis due to its superior sensitivity (96.8%) and specificity (90.8%) for distinguishing IPMN from other cystic pancreatic lesions 1
MRI with MRCP has superior ability to demonstrate ductal communication, which is crucial for IPMN diagnosis and classification 1
If MRI is contraindicated, a dual-phase contrast-enhanced pancreatic protocol CT can be used as an alternative, though it has lower sensitivity (80.6%) and specificity (86.4%) 1
EUS with possible FNA should be considered when there are worrisome features requiring tissue sampling 2

Evaluate for high-risk stigmata that warrant surgical consideration, including enhancing solid component within the cyst 1
Assess for worrisome features, including cyst size ≥3 cm 1, thickened or enhancing cyst walls 2, non-enhancing mural nodules 2, abrupt change in caliber of pancreatic duct with distal pancreatic atrophy 2, lymphadenopathy 3, and elevated serum CA 19-9 (>37 U/mL) 2

Determine if the IPMN is main duct (MD-IPMN), branch duct (BD-IPMN), or mixed type, as this significantly impacts management decisions 2
MD-IPMN and mixed-type IPMN have significantly higher malignancy risk (56-91%) compared to BD-IPMN (6-46%) 2

For BD-IPMN without high-risk features, initial follow-up at 6 months, then imaging every 6-12 months for the first 2 years, and yearly thereafter if remains stable 2
For BD-IPMN with worrisome features, more frequent follow-up every 3-6 months is recommended 2
For MD-IPMN or mixed-type IPMN, surgical consultation should be obtained as these generally warrant resection due to high malignancy risk 2, 4

Surveillance should continue lifelong as long as the patient remains fit for surgery 2, 3
Even after years of stability, do not discontinue surveillance as the risk of malignant progression increases over time 2
After partial pancreatectomy for IPMN, lifelong follow-up of the remnant pancreas is still indicated 2, 5

For tail IPMNs with high-risk features, a distal pancreatectomy with lymph node dissection and splenectomy is the standard oncologic approach 6
For tail IPMNs without suspicious features, a non-oncological resection (distal pancreatectomy with splenic preservation) may be considered 6
Parenchyma-sparing pancreatectomy may be considered in selected patients to decrease long-term diabetes risk 6